Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Acquisitions (2016)

Amphastar Pharmaceuticals (AMPH) has 3 years of Acquisitions data on record, last reported at $761000.0 in Q2 2016.

  • For Q2 2016, Acquisitions changed N/A year-over-year to $761000.0; the TTM value through Dec 2016 reached $8.3 million, changed N/A, while the annual FY2016 figure was $12.5 million, 256.03% up from the prior year.
  • Acquisitions reached $761000.0 in Q2 2016 per AMPH's latest filing, down from $4.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $6.0 million in Q4 2014 and bottomed at $761000.0 in Q2 2016.
  • Average Acquisitions over 3 years is $3.6 million, with a median of $3.8 million recorded in 2015.
  • The widest YoY moves for Acquisitions: up 41.67% in 2015, down 41.67% in 2015.
  • A 3-year view of Acquisitions shows it stood at $6.0 million in 2014, then plummeted by 41.67% to $3.5 million in 2015, then plummeted by 78.26% to $761000.0 in 2016.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $761000.0 in Q2 2016, $4.0 million in Q1 2016, and $3.5 million in Q4 2015.